# Clinical biomarkers predicting response to IVIG therapy

## Predictive biomarkers for IVIG response are disease-specific: 
Pre-treatment inflammatory markers (C-reactive protein, liver enzymes, bilirubin) predict resistance in Kawasaki disease, while post-treatment cellular immune markers (NK cells, regulatory T cells) predict response in chronic neurological autoimmune disorders.

## Abstract
Clinical biomarkers predicting IVIG response differ substantially by disease condition and reflect distinct pathophysiological mechanisms. In Kawasaki disease, pre-treatment inflammatory markers consistently predicted resistance: C-reactive protein (cut-offs 7-10 mg/dL), liver transaminases (AST ≥200 IU/L, ALT ≥80 IU/L), and total bilirubin (≥0.9 mg) demonstrated significant associations with non-response in multivariate analyses. Composite prediction scores combining multiple markers achieved 76-78% sensitivity and specificity. Post-treatment inflammatory markers measured 24 hours after infusion showed superior performance, with total leucocyte count >13.1×10⁹/L achieving 91% sensitivity and 89% specificity. In contrast, autoimmune neurological disorders demonstrated no predictive value for inflammatory markers. Instead, post-treatment cellular immune biomarkers proved informative: NK cell markers (CD56bright, KLRB1, KLRK1) measured 24 hours after IVIG initiation significantly discriminated CIDP responders from non-responders (p=0.007-0.027), while regulatory T cell frequency correlated with clinical recovery in Guillain-Barré syndrome. In dermatomyositis, higher baseline cutaneous disease activity predicted better response, whereas higher pulmonary activity predicted lower response. These divergent biomarker profiles reflect condition-specific IVIG mechanisms: acute inflammation suppression in Kawasaki disease versus immune cell modulation in chronic neurological disorders. Clinical consequences of non-response varied substantially, with Kawasaki disease non-responders experiencing coronary artery abnormalities at rates of 38-71% versus 1-5% in responders.

## Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.

## Paper search
We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of [Semantic Scholar](https://www.semanticscholar.org/) and [OpenAlex](https://openalex.org/). We ran this query: "Clinical biomarkers predicting response to IVIG therapy"

## Screening
We screened in sources based on their abstracts that met the criteria:
- **IVIG Therapy**: Study involves patients treated with IVIG therapy?
- **Biomarker-Response Relationship**: Study evaluates relationship between biomarkers and IVIG treatment response?
- **Biomarker Measurement**: Study measures clinical biomarkers?
- **Response Criteria**: Clearly defined response criteria or outcome measures for IVIG therapy?
- **Study Type**: Original research study or systematic review/meta-analysis?
- **Human Subjects**: Study involves human subjects?
- **Baseline Biomarker Assessment**: Are biomarkers measured at baseline rather than only after treatment?
- **Sample Size**: Does study include 10 or more patients?

## Data extraction
We asked a large language model to extract data from each paper regarding:
- **Medical Condition**: Indication for IVIG therapy (e.g., Guillain-Barré syndrome, Kawasaki disease).
- **Biomarker Details**: Clinical biomarkers tested for predicting IVIG response.
- **IVIG Response Definition**: How IVIG treatment response was defined and measured.
- **Biomarker Performance**: Predictive performance of each biomarker for IVIG response.
- **IVIG Protocol**: Details of the IVIG treatment protocol used.
- **Study Population**: Characteristics of the study population relevant to biomarker performance.
- **Clinical Outcomes**: Observed clinical outcomes in responders vs non-responders to IVIG.

## Results
## Characteristics of Included Studies
Ten studies investigating clinical biomarkers for predicting IVIG response were identified, spanning multiple autoimmune and inflammatory conditions.

| Study | Full text retrieved? | Medical Condition | Sample Size | IVIG Dose | Response Definition |
|-------|----------------------|-------------------|-------------|------------|-------------------|
| Y. Levy et al., 1999 | No | Systemic lupus erythematosus | 20 | 2 g/kg monthly over 5 days | Binary; clinical improvement with decreased SLAM score |
| A. Irgens et al., 2012 | No | Myasthenia gravis with worsening weakness | 51 | 2 g/kg divided over 2 days | Continuous; change in QMG Score at day 14 |
| C. Charles-Schoeman et al., 2025 | No | Dermatomyositis | 95 | 2.0 g/kg every 4 weeks | Continuous; total improvement score (TIS) |
| J. Hwang et al., 2010 | No | Kawasaki disease | 229 (206 responders, 23 non-responders) | Not specified | Binary; responder vs non-responder |
| M. Maddur et al., 2017 | Yes | Guillain-Barré syndrome | 10 | 0.4 g/kg for 3-5 consecutive days | Continuous; MRC and modified Rankin scores |
| T. Sano et al., 2006 | No | Acute Kawasaki disease | 112 | 2 g/kg within 2 days of onset | Binary; responsive vs non-responsive |
| Anne K. Mausberg et al., 2020 | Yes | Chronic inflammatory demyelinating polyneuropathy | 29 | Not specified, treatment up to 6 months | Binary; INCAT score decline ≥1 point over 6 months |
| K. Egami et al., 2006 | No | Kawasaki disease | 320 (279 responders, 41 resistant) | 2 g/kg within 9 days of illness | Binary; resistance vs responder groups |
| J. Abe et al., 2008 | No | Kawasaki disease | Not specified | High-dose (not specified) | Binary; responsive vs nonresponsive |
| Mariko Fukunishi et al., 2000 | No | Kawasaki disease | 82 (69 responsive, 13 non-responsive) | High-dose (not specified) | Binary; defervescence within 5 days |

The studies represented diverse autoimmune conditions, with Kawasaki disease being the most extensively studied. Sample sizes ranged from 10 to 320 patients. Most studies used standard high-dose IVIG protocols of 2 g/kg, though administration schedules varied.

## Predictive Biomarkers by Disease Category
### Kawasaki Disease
Five studies examined biomarkers predicting IVIG resistance in Kawasaki disease, demonstrating substantial heterogeneity in both biomarkers identified and their measurement timing.

| Study | Pre-treatment Biomarkers | Cut-off Values | Performance Metrics | Post-treatment Biomarkers |
|-------|--------------------------|----------------|--------------------|---------------------------|
| T. Sano et al., 2006 | CRP, total bilirubin, AST, ALT, LDH, neutrophil count | CRP ≥7.0 mg, TB ≥0.9 mg, AST ≥200 IU/L | Multivariate p-values: CRP (p=0.009), TB (p<0.001), AST (p=0.002) | Not assessed |
| K. Egami et al., 2006 | Age, illness days, platelet count, ALT, CRP | Age <6 months, <4 illness days, platelet ≤30×10¹⁰/L, CRP ≥8 mg/dL, ALT ≥80 IU/L | Prediction score sensitivity 78%, specificity 76% | Not assessed |
| Mariko Fukunishi et al., 2000 | CRP, total bilirubin, LDH, gamma-glutamyltranspeptidase, hemoglobin | CRP >10 mg/dL, LDH >590 IU/L, hemoglobin <10 g/dL | Multivariate p-values: CRP (p=.006), LDH (p=.035), TB (p=.046) | Not assessed |
| J. Hwang et al., 2010 | Neutrophil differential, CRP | Pre-treatment: neutrophil >51% | Not specified | Total leucocyte >13.1×10⁹/L (sens 91%, spec 89%), neutrophil >51% (sens 91%, spec 76%) |
| J. Abe et al., 2008 | Polycythemia rubra vera 1, G-CSF measured by mRNA and protein levels | Not specified | Higher in nonresponders | Not assessed |

C-reactive protein emerged as the most consistently identified pre-treatment biomarker, appearing in four of five Kawasaki studies. The optimal cutoff values varied across studies. Non-responders to IVIG consistently demonstrated worse clinical outcomes.

### Autoimmune Neurological Disorders
Three studies revealed markedly different predictive approaches.

In Guillain-Barré syndrome, regulatory T cell frequency correlated with clinical recovery, while plasma IL-33 levels showed no correlation. For CIDP, natural killer cell markers measured 24 hours post-IVIG initiation demonstrated significant association with response. Response rates varied significantly across studies, with non-responders requiring extended time for identification.

### Other Autoimmune Conditions
In systemic lupus erythematosus, autoantibodies were evaluated as predictors. In dermatomyositis, higher cutaneous disease activity predicted better response.

## Synthesis
The heterogeneity in predictive biomarkers across conditions reflects fundamental differences in disease pathophysiology, IVIG mechanisms of action, and optimal measurement timing. Clinical outcomes in IVIG non-responders varied widely, particularly noting the significant risks associated with Kawasaki disease non-responders.